IDXX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $3.94 | - | - |
| Q1'26 | $3.92 | $3.47 | -11.6% |
| Q4'25 | $2.99 | $3.08 | +3.1% |
| Q3'25 | $3.14 | $3.40 | +8.3% |
| Q2'25 | $3.30 | $3.63 | +10.0% |
| Q1'25 | $2.85 | $2.96 | +3.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.2B | - | - |
| Q1'26 | $1.2B | $1.1B | -4.8% |
| Q4'25 | $1.1B | $1.1B | -0.3% |
| Q3'25 | - | $1.1B | - |
| Q2'25 | - | $1.1B | - |
| Q1'25 | - | $998M | - |
Market Data
IDXX Stock Snapshot
IDXX is currently trading at $553.56, giving IDEXX Laboratories, Inc. a market cap of 44.12B and a P/E ratio of 40.3. Today's range spans $550.97–$559.76, with shares opening at $559.76 and moving down $5.81 (1.0%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 69/100.
Over the past year IDXX has traded between $496.61 and $769.98 - the current price is +11.5% off the 52-week low and -28.1% from the high.
The technical picture for IDXX is mixed - score 41/100, HOLD, with the stock at $553.56 (in the lower half of its 52-week range) and sentiment bullish at 69/100. For a large-cap in Healthcare with 44.12B in capitalization The current P/E ratio stands at 40.3., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $496.61–$769.98. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.
Portfolio construction in Healthcare often uses large-cap names like IDXX as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 41/100 (HOLD) at $553.56 (in the lower half of its 52-week range) and bullish sentiment (69/100) frame the position as a catalyst play within the $496.61–$769.98 annual range rather than a directional bet.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).